A Randomised Controlled Trial to Compare Unfractionated Heparin Versus Bivalirudin in the Treatment of Patients With a Clinical Diagnosis of ST-Segment Elevation Myocardial Infarction Events - For Planned Management With Primary PCI.
Latest Information Update: 15 Dec 2022
Price :
$35 *
At a glance
- Drugs Bivalirudin (Primary) ; Heparin
- Indications Embolism and thrombosis; Myocardial infarction
- Focus Adverse reactions; Therapeutic Use
- Acronyms HEAT-PPCI
- 07 Nov 2022 Results of pooled subgroup analysis (n=15254) assessing efficacy of bivalirudin versus heparin in patients with STEMI undergoing PCI from BRIGHT, EUROMAX, HEAT-PPCI, HORIZONS-AMI, MATRIX, and VALIDATE-SWEDEHEART studies, presented at the American Heart Association Scientific Sessions 2022.
- 30 Oct 2015 Results published early online in the Lancet
- 01 Dec 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.